The company, together with the listed company Erkang pharmaceutical and Shaanxi therapeutic vaccine Engineering Technology Research Center, has established a drug slow control technology platform for polypeptide and protein macromolecular drugs based on PLGA, sodium hyaluronate gel and other excipients, forming an intellectual property protection alliance of excipient product linkage. It was supported by the national "major new drug discovery" (national approval number: 2013ZX09509106). On September 2, the drug and medical device uation system ushered in the first major adjustment in nearly five years. On August 18, the State Council issued the Opinions on the Reform of the Drug and Medical Device uation and Approval System, which clearly pointed out that the definition of new drugs was changed from the current "drugs that have not been marketed in China" to "drugs that have not been marketed in China and abroad", At the same time, it is stipulated that scientific researchers of R&D institutions can hold the marketing license of new drugs, optimize the approval procedures for innovative drugs, and allow overseas unlisted new drugs to carry out clinical trials in China after approval. For this, the industry has gradually formed such a consensus that new drug research and development will play an increasingly important role in the development of Chinese pharmaceutical enterprises.